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In this issue, Puri et al. (2010) present inhibitors that prevent the autocatalytic activation of the clostridial toxin
TcdB in vivo. Their approach is likely to provide guidance for the development of novel drugs targeting
virulence factors and thereby rendering bacterial pathogens innocuous.Nosocomial infections caused by the
bacterial pathogen Clostridium difficile
are increasing worldwide due to the pres-
ence of hypervirulent and multiresistant
strains. Colonization of C. difficile usually
occurs in the colon if the natural gut flora
is diminished by treatment with antibi-
otics. An infection can lead to antibiotic-
associated diarrhea and sometimes
pseudomembranous colitis through the
secretion of the large glucosylating toxins
TcdA and TcdB, which constitute the
primary virulence factors of C. difficile.
During the last decade, several outbreaks
of the hypervirulent Quebec strain ‘‘NAP1/
027,’’ which produces these toxins at
drastically elevated levels, have lead to
numerousdeaths in hospitals in theUnited
States, Canada, the United Kingdom, the
Netherlands, Germany, and Finland
(O’Connor et al., 2009).
TcdA and TcdB have a multidomain
structure for which an ABCD model
(activity, receptor binding, cleavage,
delivery) was proposed by Jank and Akto-
ries (2008). The mechanism of TcdB
action is believed to be a five-step
process. First, the C-terminal receptor-
binding domain of TcdB binds to an extra-
cellular carbohydrate-based receptor.
This binding triggers off endocytosis that
leads to cellular uptake of the toxin. Acid-
ification of the endosome is thought to
initiate a conformational rearrangement
within the second domain, which
comprises a hydrophobic region that
penetrates the membrane and presum-
ably exposes the two N-terminal domains
to the cytosol. Release of the effector
domain, i.e., the N-terminal glucosyl-
transferase (GT) domain, is achieved by
an autocatalytic cleavage mediated by
a cysteine protease domain (CPD). The
presence of the GT domain in the cytosol
leads to the glycosylation of several RhoGTPases that cause alterations of the
actin cytoskeleton and ultimately cell
death. TcdB arguably has one of the
most elegant mechanisms of activation:
the autocatalytic cleavage event carried
out by the CPD is triggered by the eukary-
otic-specific cytosolic small molecule
inositol hexakisphosphate (InsP6). Thus,
InsP6 serves as a signal that the toxin
has arrived at its destination.
In a study published in this issue, Puri
et al. (2010) have designed inhibitors and
activity-based probes to inhibit this auto-
catalytic cleavage. Using a gel-based
assay that visualizes the protein frag-
ments formed upon autocleavage, they
have identified dipeptide and tripeptide
acyloxymethyl ketone (AOMK)-based
inhibitors that are able to block toxin acti-
vation in the presence of InsP6. AOMKs
form a covalent intermediate with the
nucleophilic active site cysteine residue
of the protease that blocks binding of
the natural cleavage site. During two
rounds of structural optimization, they
subsequently synthesized a small
focused library of AOMK-inhibitors and
assessed their potency with the auto-
cleavage assay, yielding Hpa-SerLeu-
AOMK as the most potent inhibitor with
an in vitro IC50 value of 0.71 mM.
In order to determine the potency of
their inhibitors in vivo, Puri et al. (2010)
developed a cell-based assay in which
fibroblasts were pretreated with an
AOMK inhibitor and then exposed to re-
combinant full-length TcdB. As cell intox-
ication leads to the disruption of the actin
cytoskeleton, changes in cell morphology
can be used to measure toxin activation.
The authors were able to show that the
potencies determined in vitro correlated
with the results in vivo with noncytotoxic
Hpa-SerLeu-AOMK completely inhibiting
toxin function at 100 mMwith an observedChemistry & Biology 17, November 24, 2010 ªIC50 of 20 mM. Hence, they could validate
the CPD as a viable drug target, even
though the drug has to compete with an
autocatalytic substrate necessitating
a high concentration of the inhibitor.
The report also includes a crystal struc-
ture of the TcdB-CPD bound to an Ac-
GlySerLeu-AOMK inhibitor and InsP6. A
highly hydrophobic pocket accompa-
nying the inhibitor leucine side chain and
observed back-bone hydrogen bonding
for the P2 and P3 residues Ser and Gly,
respectively, provide the structural basis
of CPD substrate recognition. Binding of
InsP6 occurs in a highly basic cage that
comprises several arginine and lysine
residues and shows a high resemblance
to the respective site in Vibrio cholera
MARTX toxin CPD (Lupardus et al.,
2008). Molecular docking based on the
crystal structure was used to rationalize
the measured potencies of the AOMK
library.
In pursuit of a tool that allows for the
direct visualization of CPD activity, Puri
et al. (2010) turned their inhibitor into the
activity-based probe AWP19 by replacing
the N-terminal capping group with
a spacer and a Cy5 fluorophore. AWP19
was found to fluorescently label holotoxin
at probe concentrations below 50 nM.
The probe was furthermore used to char-
acterize cathepsin B as a possible off-
target of TcdB CPD inhibitors. Due to
the short specificity region of only two
amino acids, cross-reactivity must be
considered and could also account for
the cytotoxicity of the Cbz-SerLeu-
AOMK inhibitor that only differs in the
capping group from the noncytotoxic
lead compound Hpa-SerLeu-AOMK.
However, this result will hopefully aid the
development of more advanced probes
that could enable the direct visualization
of toxin activation at a single-toxin level,2010 Elsevier Ltd All rights reserved 1165
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where CPD activation takes place in the
cell.
The observation that the CPD alone is
more effectively labeled than the auto-
cleavage substrate led the authors to
speculate about a conformational regula-
tion of toxin activity. This is based on the
assumption that in the full length toxin
the natural cleavage site is located close
to the active site, reducing its accessi-
bility, e.g., for CPD inhibitors. Hence,
a clinically applicable CPD inhibitor will1166 Chemistry & Biology 17, November 24,have to cope with the tough task of both
competing with an autocatalytic substrate
and reacting with a rather unreactive
protease. However, Puri et al. (2010)
have demonstrated that it is possible to
take up this challenge. Their promising
approach is likely to provide guidance
for the development of a new generation
of drugs targeting C. difficile virulence
factors rather than cellular viability,
thereby rendering this important bacterial
pathogen innocuous (Clatworthy et al.,
2007).2010 ª2010 Elsevier Ltd All rights reservedREFERENCES
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In global proteomic applications that focus on the characterization of proteins that have been derivatized
using bioorthogonal chemistry, a challenge persists in the release of labeled proteins from supports used
for purification. In this issue, Yang and coworkers (2010) present a detailed study of the diazobenzene-cleav-
able linker system as an effective solution for proteomic studies.In recent years, critical technical advances
have profoundly enhanced the ability to
perform global analysis of biological
systems, including novel bioorthogonal
labeling reactions and mass spectrom-
etry-based proteomic techniques. For
the former, the ability to achieve selective
labeling of biomolecules within the ex-
tremely complex environments of organ-
isms, cells, and cell extracts has opened
numerous avenues for the efficient char-
acterization of biological systems. Here,
bioorthogonal reactions, including the azi-
dealkyne cycloadditions, either the
copper-catalyzed or copper-free reac-
tions, as well as the Staudinger Ligation,
have emerged as vital chemical tools
(Sletten and Bertozzi, 2009). In examples
of powerful applications, the analogs of
sugars (Saxon and Bertozzi, 2000), amino
acids (Link et al., 2003; Liu and Schultz,
2010), and lipids (Kho et al., 2004; Hang
et al., 2007) bearing diminutive reactivetags that represent only minor structural
perturbations (azide or alkyne) have been
shown to effectively infiltrate biosynthetic
pathways. This has been exploited to
achieve the bioorthogonal labeling of re-
sulting cell surface glycoproteins, newly
synthesized proteins, and posttransla-
tionally lipidated proteins, respectively. In
addition, the strategy of activity-based
protein profiling has been advanced for
the collective labeling of proteins using
small molecule probes that label target
proteins (Speers et al., 2003; Cravatt
et al., 2008).
Despite these advances, technical
challenges persist that complicate such
applications, particularly when the goal
is to isolate and identify labeled proteins
and to characterize the location of the
labeling event. For this purpose, bioor-
thogonal chemistry is typically used to
introduce biotin onto labeled proteins, fol-
lowed by subsequent purification viastreptavidin enrichment (Figure 1).
However, a problem exists: it is chal-
lenging to achieve quantitative release of
proteins from avidin supports after purifi-
cation due to the high affinity of the strep-
tavidinbiotin interaction. As a result,
there has been considerable interest in
devising cleavable affinity tags to release
proteins following the labeling and purifi-
cation stages. To be effective, this chem-
istry must survive all aspects of the
labeling and separation processes, but
must be cleanly released using mild
conditions so as not to affect labeled
proteins and subsequent mass spectrom-
etry-based detection. In this issue of
Chemistry and Biology, Yang and
coworkers (2010) present a detailed study
of a diazobenzene system that is shown to
be highly effective for cleavage in sophis-
ticated proteomics applications.
In the article, Yang and coworkers
(2010) describe the design, synthesis,
